in Boston has announced a four-year, $20 million grant from the to evaluate and test broadly neutralizing monoclonal antibodies for the treatment of HIV.
The grant will support proof-of-concept studies in monkeys and the launch of Phase 1 and Phase 2 clinical trials in HIV-infected humans. Based on data from the studies, investigators will examine whether PGT121, either alone or in combination with other monoclonal antibodies, will suppress or eradicate HIV in humans. The team also will investigate the use of PGT121 in conjunction with antiretroviral therapy to reduce viral reservoirs that persist with ART alone.
"We have recently demonstrated the profound therapeutic efficacy of the potent broadly neutralizing monoclonal antibody PGT121 in rhesus monkeys chronically infected with a monkey version of human HIV," said Dan Barouch, M.D., Ph.D., principal investigator of the project and director BIDMC's .